Loading provider…
Loading provider…
Hematology & Oncology Physician in Los Angeles, CA
NPI: 1659303873Primary Employer
USC Care Medical Group, Inc
keckmedicine.org
HQ Phone
Get MD Greg's Phone NumberMobile
Get MD Greg's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
2011 - 2027
CT State Medical License
2004 - 2011
MD State Medical License
2001 - 2004

American Board of Internal Medicine
Internal Medicine

American Board of Internal Medicine
Hematology
Johns Hopkins University
Fellowship • Hematology and Medical Oncology
2001 - 2004
WashU Medicine
medicine.washu.edu
Medical School
Until 1997
Washington University/B-JH/SLCH Consortium
Residency • Internal Medicine
1997 - 2000
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99213Established patient office or other outpatient visit, typically 15 minutes | 459 | 954 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 361 | 1,027 |
| 3 | 99215Established patient office or other outpatient, visit typically 40 minutes | 103 | 292 |
| 4 | 99204New patient office or other outpatient visit, 45-59 minutes | 98 | 98 |
| 5 | 99443Physician telephone patient service, 21-30 minutes of medical discussion | 62 | 83 |
Treatment options for chronic myeloid leukemia: imatinib versus interferon versus allogeneic transplant.
Authors: Greg R. Angstreich, B. Douglas Smith, Richard J. Jones
Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors.
Authors: Carol Huff, William Matsui
Journal: Br J Haematol
Lead Sponsor: University of Southern California
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: OTHER: Biomarker Analysis, OTHER: Cytology Specimen Collection Procedure
Lead Sponsor: University of Southern California
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: OTHER: Placebo, OTHER: Laboratory Biomarker Analysis, DRUG: Axitinib, BIOLOGICAL: Anti-OX40 Antibody PF-04518600
Lead Sponsor: University of Southern California
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: BIOLOGICAL: Recombinant EphB4-HSA Fusion Protein, OTHER: Laboratory Biomarker Analysis, BIOLOGICAL: Pembrolizumab, PROCEDURE: Positron Emission Tomography, PROCEDURE: Computed Tomography